Skip to main content
Figure 2 | BMC Cancer

Figure 2

From: Enhanced tumour cell nuclear targeting in a tumour progression model

Figure 2

Tumour cell enhanced nuclear targeting conferred by the Apoptin-tNTS is observed in a breast cancer tumour progression model and can be conferred to histones H3 and H2B. A. MCF10A (normal), MCF10AT (pre-malignant) or MCF10Ca1h (tumour) cells were transfected for 6 h to express the indicated fusion proteins followed by CLSM analysis. B. Digitised images as those shown in A were analysed to determine relative levels of nuclear accumulation displayed as mean Fn/c ± SEM (n > 40) where p values indicate significant differences determined by the students t-test. C. CCIs of the results shown in B, determined from a ratio of the Fn/c values. Results are from a single typical experiment from a series of three similar experiments. D. MCF10A (normal), MCF10AT (pre-malignant) or MCF10Ca1h (tumour) cells were transfected for 6 h to express the indicated fusion proteins. E. Digitised images as those shown in D were analysed to determine relative levels of nuclear accumulation displayed as mean Fn/c ± SEM (n > 40) where p values indicate significant differences determined by the students t-test. F. CCIs of the results shown in E, determined from a ratio of the Fn/c values. Results are from a single typical experiment from a series of two similar experiments.

Back to article page